Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Lisata Therapeutics ( (LSTA) ).
On January 22, 2025, Lisata Therapeutics announced preliminary positive results from Cohort A of the Phase 2 ASCEND trial for its investigational drug certepetide in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma. The data showed a median overall survival of 12.68 months for the certepetide group compared to 9.72 months for the placebo group, with four complete responses observed in the certepetide group. The findings are expected to support further development into Phase 3 trials, with data from Cohort B anticipated in the coming months, potentially enhancing the company’s standing in the oncology market.
More about Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors and other major diseases. Its investigational drug, certepetide, is designed to enhance the targeting and penetration of anti-cancer drugs into solid tumors, leveraging its CendR Platform® technology for advanced drug delivery.
YTD Price Performance: 9.24%
Average Trading Volume: 32,603
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $32.74M
For an in-depth examination of LSTA stock, go to TipRanks’ Stock Analysis page.
